$Replimune (REPL.US)$Reuters· 3 mins ago Replimune Receives Breakthrough Therapy Designation for Rp1 and Submits Rp1 Biologics License Application to the FDA Under the Accelerated Approval Pathway
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.